An artificial autophagy targeting chimera and its preparation method and application

By combining guanine derivatives with nucleoside anti-tumor drugs to form carrier-free nanoparticles, and using autophagosome to degrade target proteins, the problem of high concentration and drug resistance in the existing technology is solved, and efficient degradation and immunity are achieved Combination therapy simplifies the preparation process and reduces toxicity.

CN116570565BActive Publication Date: 2024-11-15SICHUAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310641296.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-05-31
Publication Date
2024-11-15
Estimated Expiration
2043-05-31

AI Technical Summary

Technical Problem

Existing small-molecular inhibitors and antibody drugs require high concentrations when inhibiting pathogenic proteins and easily lead to drug resistance. AUTAC technology has low bioavailability and poor pharmacokinetics due to its large molecular weight. There is a drug loading in nanocarrier delivery systems. Low and toxicity problems make it difficult to effectively degrade target proteins.

Method used

Design an artificial autophagy-targeted chimera, which combines guanine derivatives with nucleoside antitumor drugs through base complementary pairing to form carrier-free nanoparticles, and uses the autophagosome pathway to degrade target proteins to avoid drug resistance and improve bioavailability.

Benefits of technology

It has achieved efficient degradation of target proteins at low doses, activates immune function, reduces the toxic and side effects of chemotherapy drugs, simplifies the preparation process, overcomes the complexity and potential toxicity of the carrier delivery system, and improves the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116570565B_ABST
    Figure CN116570565B_ABST
Patent Text Reader

Abstract

The present invention discloses an artificial autophagy targeting chimera and a preparation method and application thereof. The preparation method of the artificial autophagy targeting chimera comprises the following steps: dissolving a guanine derivative molecule and a nucleoside anti-tumor drug in an organic solvent respectively, mixing the two solutions, ultrasonically treating them, and then dropping them into deionized water for self-assembly to form carrier-free nanoparticles, namely, artificial autophagy targeting chimeras. In the present invention, the carrier-free nanoparticles formed by self-assembly of guanine derivatives and nucleoside anti-tumor drugs by base pairing 1:1 have the advantages of simple preparation, high drug loading, good stability, etc. The nanoparticles can not only activate the body's immunity while using anti-tumor drugs to kill tumor cells, but also specifically degrade intracellular immune checkpoint proteins to enhance the body's immune response ability, thereby realizing combined immune therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to an artificial autophagy targeting chimera and a preparation method and application thereof. Background Art

[0002] The precise regulation of protein synthesis and degradation by the body is the key to maintaining the normal life activities of cells and organisms. When the body overexpresses or activates proteins, various diseases follow. At present, more than 3,000 proteins are known to be associated with diseases, including malignant tumors, autoimmune diseases, neurodegenerative diseases and cardiovascular diseases. Selectively inhibiting or degrading pathogenic proteins will help to achieve disease treatment. Protein activity regulators that inhibit pathogenic proteins are the mainstream of traditional drug development, mainly including small molecule inhibitors and antibody drugs. Their mechanism of action is to specifically bind to the active site of the target protein, prevent the substrate from entering the catalytic / active site, thereby inhibiting the activity of the protein. As an important part of the medical field, they have been successfully used in the treatment of tumors, autoimmune diseases and infectious diseases. However, the development of small molecule drugs and antibody drugs still faces many bottlenecks. On the one hand, this "occupancy-driven" pharmacological paradigm between small molecule inhibitors and antibodies and target proteins usually requires higher concentrations to work effectively, further increasing the risk of drug target mutations and ultimately leading to drug resistance. On the other hand, most pathogenic proteins (80% to 85%) lack clear binding pockets, making it difficult for small molecules or antibody drugs to bind to the target protein to exert their effects. Therefore, new technologies are urgently needed to solve the challenges faced by small molecules or antibody drugs.

[0003] In recent years, targeted protein degradation technology (PPD) that uses the naturally existing protein degradation system (ubiquitination-proteasome system and lysosomal degradation pathway) in cells to consume or reduce pathogenic proteins has developed rapidly. It can recruit E3 ligases to the vicinity of target proteins and ubiquitinate target proteins, directly degrading disease-related proteins specifically and efficiently at the protein level, thereby achieving the effect of disease treatment. Unlike the occupancy-driven mode of small molecules and antibody drugs, the event-driven mode of proteolysis targeting chimeras (PROTACs) do not need to bind to the target protein for a long time to work, with higher activity and selectivity, and can be achieved at lower doses. Among them, the autophagy-targeted chimera (AUTAC) technology is a PROTAC designed based on the autophagy mechanism of the body to clear group A Streptomyces (GAS). It mainly consists of three parts, namely, the ligand of the targeted protein, the linker, and the degradation tag guanine derivative (GD). The principle of this technology is to simulate S-guanylate modification through degradation tags, induce K63 polyubiquitination tagging of target proteins (POIs), and then recruit autophagosomes for degradation through the lysosomal pathway. Based on the above background, by connecting the degradation tag guanine derivative to the target protein binding part, the degradation of specific proteins can be achieved, avoiding the drug resistance caused by site mutations. Although there has been great progress, AUTAC technology still has many problems. The excessive molecular weight of AUTAC makes it face problems such as low bioavailability, poor pharmacokinetics and off-target effects, which in turn leads to limited degradation efficiency.

[0004] The development of nano drug delivery systems provides a new approach to overcoming the difficulties faced by such drug preparations. Carrier drug delivery systems such as liposomes, polymer nanoparticles and inorganic nanoparticles can not only enhance the biostability and bioavailability of therapeutic drugs, but also significantly reduce the toxicity of drugs to the body. Although carrier drug delivery systems have many advantages, they still have problems such as low drug loading, poor stability and sudden release of drugs in non-tumor sites. At the same time, the proportion of nanocarriers is too high and the metabolism, degradation and excretion mechanisms in the body after depolymerization are unclear, which may cause short-term and long-term toxicity to multiple systems of the human body during the treatment process. In addition, the complex carrier synthesis process and large batch differences have greatly limited the clinical transformation of carrier drug delivery systems.

[0005] In view of the above-mentioned shortcomings of the prior art, a carrier-free nano-delivery system with simple preparation method, high drug loading and good biological activity has emerged. A carrier-free nano-delivery system refers to a prodrug, a pure drug (such as a single drug or multiple drugs) or an amphiphilic drug-drug conjugate, etc., which is directly self-assembled through non-covalent forces such as hydrophobic interactions, electrostatic interactions or hydrogen bonds of the drug itself.

[0006] However, there are no reports on combining guanine-like substances with nucleoside drugs to prepare carrier-free nanoparticles. Summary of the invention

[0007] In order to solve the above-mentioned deficiencies in the prior art, the purpose of the present invention is to provide an artificial autophagy targeting chimera and a preparation method and application thereof. Based on the AUTAC technology, the present invention designs and synthesizes guanine derivative molecules, which are combined with nucleoside anti-tumor drugs through base complementary pairing to prepare carrier-free nanoparticles, thereby achieving degradation of the target protein and avoiding drug resistance caused by site mutations.

[0008] The technical solution of the present invention to solve the above technical problem is as follows: a method for preparing an artificial autophagy targeting chimera is provided, comprising the following steps:

[0009] Guanine derivatives and nucleoside anti-tumor drugs are dissolved in organic solvents respectively, the two solutions are mixed, ultrasonically treated, and then dropped into deionized water for self-assembly to form carrier-free nanoparticles, namely artificial autophagy targeting chimeras.

[0010] Further, the structural formula of the guanine derivative is as follows:

[0011]

[0012] Further, the guanine derivative is prepared by the following method:

[0013]

[0014] (i) Compound 1 (6-chloroguanine) is dissolved in a solvent, and then 4-fluorobenzyl alcohol and a base are added to react at room temperature to obtain Compound 2;

[0015] (ii) Compound 2 is refluxed with hydrochloric acid to obtain compound 3;

[0016] (iii) Compound 3, N-bromosuccinimide and glacial acetic acid are reacted at room temperature to obtain compound 4;

[0017] (iv) Compound 4, N-acetyl-L-cysteine ​​and a base are dissolved in a solvent and reacted at 85-95° C. to obtain Compound 5;

[0018] (v) dissolving compound 5, HATU, DIPEA and NLG8189 in a solvent and reacting at room temperature to obtain compound 6;

[0019] (vi) Compound 6 is dissolved in a solvent, and then hydrated lithium hydroxide is added to react at room temperature to obtain a guanine derivative.

[0020] Furthermore, in step (i), the molar ratio of compound 1, 4-fluorobenzyl alcohol and base is 1:1-2:1-2; and the reaction is carried out at room temperature for 12-18 hours.

[0021] Furthermore, in step (i), the solvent is DMF, and the base is potassium carbonate, sodium carbonate, etc.

[0022] Furthermore, in step (ii), reflux is performed for 2-3 hours.

[0023] Furthermore, in step (iii), the molar ratio of compound 3 to N-bromosuccinimide is 1:1.5-2; and the reaction is carried out at room temperature for 20-24 hours.

[0024] Furthermore, in step (iv), the molar ratio of compound 4, N-acetyl-L-cysteine ​​and base is 1:3-5:12-15; the reaction is carried out at 85-95° C. for 4-6 hours.

[0025] Furthermore, in step (iv), the solvent is N,N-dimethylformamide or the like, and the base is potassium carbonate, sodium carbonate or the like.

[0026] Furthermore, in step (v), the molar ratio of compound 5, HATU, DIPEA and NLG8189 is 1:1-2:1.5-2.5:2-4; and the reaction is carried out at room temperature for 1-3 hours.

[0027] Furthermore, in step (v), the solvent is DMF or the like.

[0028] Furthermore, the nucleoside anti-tumor drug is methotrexate (MTX), cytarabine, doxifluridine or decitabine.

[0029] Further, the guanine derivative molecules are dissolved in an organic solvent to obtain a guanine derivative solution with a concentration of 8-12 mg / mL.

[0030] Furthermore, the nucleoside anti-tumor drug is dissolved in an organic solvent to obtain a nucleoside anti-tumor drug solution with a concentration of 8-12 mg / mL.

[0031] The guanine derivative solution and the nucleoside anti-tumor drug solution are mixed in a 1:1 ratio according to the complementary base pairing between the nucleotides.

[0032] Furthermore, before the ultrasonic treatment, an alkaline solution is added to the system and the system is continuously mixed before the ultrasonic treatment.

[0033] Furthermore, the alkaline solution is a NaOH solution with a concentration of 3-6 mg / mL.

[0034] Furthermore, the ultrasonic treatment time is 10-20 min.

[0035] Furthermore, the method further comprises: performing dialysis to remove the organic solution after the self-assembly reaction.

[0036] The use of the artificial autophagy targeting chimera prepared above in the preparation of drugs for degrading pathogenic proteins.

[0037] Furthermore, the artificial autophagy targeting chimera prepared as above is used in the preparation of drugs for treating and / or preventing diseases related to immune checkpoint proteins indoleamine 2,3-dioxygenase (IDO) or programmed death ligand (PD-L1).

[0038] The present invention has the following beneficial effects:

[0039] The present invention takes the immune checkpoint protein IDO as an example, and designs an AUTAC molecule that can specifically degrade IDO protein; taking the nucleoside anti-tumor drug methotrexate (MTX) as an example, the base pairing effect is used to self-assemble with the guanine part of the AUTAC molecule to form carrier-free nanoparticles. The AUTAC molecules designed and synthesized by the present invention can specifically degrade IDO protein, and the carrier-free nanoparticles formed by the base complementary pairing effect not only increase the permeability of guanine derivatives to biomembranes, but also effectively degrade the IDO protein of tumors, activate the function of effector T cells and natural killer T cells, and increase the concentration of chemotherapy drugs MTX in tumor sites, reduce its distribution in normal tissues, and thus reduce toxic side effects, and finally achieve the combined effect of chemotherapy and immunity. The preparation method of carrier-free nanoparticles mediated by base complementary pairing provided by the present invention has the advantages of simple preparation process, rapidity and universality, and can overcome the challenges of complex nanocarrier synthesis process and potential toxicity.

[0040] The carrier-free nanoparticles provided by the present invention are composed of the AUTAC molecule GN and the nucleoside antitumor drug MTX. GN is a guanine derivative, which simulates S-guanylylation modification through degradation tags, induces K63 polyubiquitination tagging of IDO protein, and then recruits autophagosomes for degradation through the lysosomal pathway; MTX is a folic acid analog, which inhibits the synthesis of tumor cells by inhibiting dihydrofolate reductase, thereby inhibiting the growth and reproduction of tumor cells.

[0041] The guanine degradation tag in the AUTAC molecule can interact with nucleoside drugs through base pairing, recognize each other, and self-assemble into an artificial autophagy-targeted chimera with a nanostructure. This base pairing self-assembly system not only has the advantages of traditional carrier drug delivery systems, but also eliminates the potential toxicity of the carrier to the body. At the same time, it overcomes the bottleneck problems of low bioavailability and off-target effects faced by existing AUTAC molecules in degrading target proteins, greatly promoting the development of AUTAC technology in the field of degrading disease-related proteins.

[0042] The carrier-free nanoparticles formed by 1:1 self-assembly of guanine derivatives and nucleoside anti-tumor drugs in the present invention have the advantages of simple preparation, high drug loading, good stability, etc. The nanoparticles can not only activate the body's immunity while using anti-tumor drugs to kill tumor cells, but also specifically degrade intracellular immune checkpoint proteins to enhance the body's immune response ability, thereby achieving combined immune therapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 This is the NMR data result of GN in Example 1.

[0044] Figure 2 The figure shows the Western blot results of different concentrations of GN degrading IDO enzyme in 4T1 cells.

[0045] Figure 3 The figure shows the flow cytometry results of different concentrations of GN degrading IDO enzyme in 4T1 cells.

[0046] Figure 4 HPLC analysis of IDO degradation in 4T1 cells by different concentrations of GN

[0047] Figure 5 This is the particle size result diagram of GM nanoparticles.

[0048] Figure 6 This is a transmission electron microscopy image of GM nanoparticles.

[0049] Figure 7 The graph shows the change in particle size of GM nanoparticles in PBS and HEPES solutions over time.

[0050] Figure 8 This is a diagram showing the results of exploring the self-assembly mechanism of GM nanoparticles.

[0051] Fig. 9 This is the in vitro fluorescence imaging of GM nanoparticles.

[0052] Fig.10 This is a semi-quantitative fluorescence image of GM nanoparticles in vitro. DETAILED DESCRIPTION

[0053] The following examples are only used to explain the present invention and are not intended to limit the scope of the present invention. If no specific conditions are specified in the examples, the conditions are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0054] Example 1: Synthesis and characterization of GN

[0055] GN is a guanine derivative with the following general structural formula:

[0056]

[0057] The specific synthesis process of GN is as follows:

[0058]

[0059] (i) Compound 1 6-chloroguanine (8.5 g, 50 mmol) was dissolved in 85 mL N,N-dimethylformamide solution, and 1-bromomethyl-4-fluorobenzene (9.45 g, 50 mmol) and potassium carbonate (6.9 g, 50 mmol) were added to the mixed solution, and stirred at room temperature for 15 h. After the reaction was completed, the N,N-dimethylformamide solvent was evaporated to dryness under reduced pressure, and the residue was purified by column chromatography to obtain a white solid product 6-chloro-9-(4-fluorobenzyl)-9H-purine-2-amine (Compound 2, 9.4 g, yield 68%);

[0060] (ii) Compound 2 (115 mg, 0.4 mmol) was mixed with 3 mL of hydrochloric acid (3 mol / L) and refluxed for 2 h. After the reaction was complete, the reaction solution was cooled to room temperature, and then about 9 mL of sodium hydroxide aqueous solution (1 mol / L) was added to neutralize it to neutrality. The precipitated white solid was collected by filtration under reduced pressure, and the filter cake was washed with a small amount of water and dried in a vacuum drying oven at 60°C to obtain a white solid product compound 3 (108 mg, yield 100%);

[0061] (iii) Compound 3 (108 mg, 0.4 mmol) was mixed with 4.2 mL of acetic acid, and N-bromosuccinimide (106.8 mg, 0.6 mmol) was added, and stirred at room temperature for 22 h. After the reaction was complete, ice water was added to the reaction solution, and a yellow turbidity appeared. The precipitated solid was collected by filtration under reduced pressure, and the filter cake was washed with a small amount of water and methanol in turn, and then the washed filter cake was placed in a vacuum drying oven and dried to obtain a white solid product, Compound 4 (55 mg, yield 40%);

[0062] (iv) Compound 4 (45 mg, 0.13 mmol) was mixed with N-acetyl-L-cysteine ​​(85 mg, 0.52 mmol) and potassium carbonate (233 mg, 1.69 mmol), and 3 mL of N,N-dimethylformamide was added, and the mixture was heated and stirred at 90°C for 5 h. After the reaction was complete, 10 mL of water was added to dilute the mixture, and hydrochloric acid (6 mol / L) was added dropwise to adjust the pH to 5-6. The precipitated solid was collected by filtration under reduced pressure, and the filter cake was washed with a small amount of water and methanol in turn. The washed filter cake was placed in a vacuum drying oven for drying to obtain a yellow solid product, Compound 5 (20 mg, yield 36%);

[0063] (v) Compound 5 (50 mg, 0.12 mmol), NLG8189 (28 mg, 0.12 mmol), HATU (68 mg, 0.18 mmol) and DIPEA (47 mg, 0.36 mmol) were dissolved in 4 mL of DMF and stirred at room temperature for 2 h. After the reaction was complete, the mixture was diluted with water and extracted twice with DCM / MeOH (10 / 1). The extracts were combined and concentrated to dryness. The residue was purified by column chromatography to obtain compound 6 (46 mg, off-white solid, yield 60%);

[0064] (vi) Compound 6 (40 mg, 0.063 mmol) was dissolved in ethanol aqueous solution (4 mL / 1 mL), and then hydrated lithium hydroxide (14 mg, 0.32 mmol) was added and reacted at room temperature for 1 h. After the reaction was complete, the pH was adjusted to 5-6 with hydrochloric acid (1 mol / L) solution, and then concentrated to dryness. The residue was purified by column chromatography to obtain a guanine derivative (16 mg, off-white solid, yield 40%).

[0065] GN's NMR data are as follows Figure 1 As shown, it means that GN was successfully synthesized.

[0066] Example 2: Ability of GN to degrade IDO protein in 4T1 cells

[0067] Western blot was used to investigate the expression of IDO protein in 4T1 cells after they were treated with different concentrations of GN. 5 4T1 cells were seeded in a 6-well plate at a density of 100 cells / well and cultured for 36 hours. Then, RPMI-1640 complete medium containing IFN-γ (100 ng / mL) was used to culture different concentrations of GN solution (10nM~10μM), and a negative control group (without IFN-γ) and a positive control group (containing only IFN-γ without drug GN) were set up. After incubation for 24 hours, the cells were collected and the total protein of 4T1 cells was extracted for Western blot analysis. The experimental results are shown in Figure 2. Figure 2 As shown, GN showed the ability to reduce the expression of IDO protein in 4T1 cells in a concentration-dependent manner.

[0068] Flow cytometry was used to investigate the expression of IDO protein in 4T1 cells after they were treated with different concentrations of GN. 44T1 cells were seeded in a 12-well plate at a density of 100 cells / well and cultured for 36 hours. Then, RPMI-1640 complete medium containing IFN-γ (100 ng / mL) was used to culture GN solutions of different concentrations (10nM~10μM), and a negative control group (without IFN-γ) and a positive control group (containing only IFN-γ without drug GN) were set up. In addition, the IDO inhibitor NLG8189 was set up as a control group. After incubation for 24 hours, the cells were collected and stained with IDO antibodies coupled to APC fluorescent molecules, and analyzed by flow cytometry. The experimental results are as follows. Figure 3 As shown, GN showed a concentration-dependent effect in reducing the expression of IDO protein in 4T1 cells, while the effect of NLG8189 in reducing IDO expression was not as good as that of GN.

[0069] High performance liquid chromatography was used to investigate the function of IDO protein in 4T1 cells after they were treated with different concentrations of GN. IDO protein can catalyze the conversion of tryptophan (an essential amino acid for T cell function) into kynurenine. On the one hand, it consumes tryptophan to inhibit the function of T cells. On the other hand, the accumulation of kynurenine also triggers the proliferation of Treg cells and inhibits the body's immune response. The function of IDO protein can be characterized by analyzing the content ratio of tryptophan and kynurenine in the cell culture supernatant through high performance liquid chromatography. Collect the cell culture supernatant, filter it, and inject it for detection. The conditions of high performance liquid chromatography are: acetonitrile: 15mM sodium acetate solution (0.02% acetic acid) = 8:92, column temperature is 25°C, flow rate is 1mL / min, tryptophan and kynurenine are detected at 280nm and 360nm, respectively. The experimental results are as follows. Figure 4 As shown, GN inhibited the function of IDO in 4T1 cells in a concentration-dependent manner, while the effect of NLG8189 in inhibiting IDO expression was not as good as GN.

[0070] Example 3: Preparation of artificial autophagy targeting chimeras

[0071] GN is a guanine derivative, which simulates S-guanylate modification through degradation tag, induces K63 polyubiquitination tag of IDO protein, and then recruits autophagosome for degradation through lysosomal pathway; MTX is a folic acid analog and also an anti-tumor drug. The artificial autophagy targeting chimera of the present invention is formed by combining GN and nucleoside anti-tumor drug MTX in the form of base complementary pairing, that is, GN and MTX are combined in a 1:1 ratio through base complementary pairing between nucleotides. The specific process is as follows:

[0072] GN was dissolved in DMSO so that the concentration of the GN solution was 10 mg / mL;

[0073] Dissolve MTX in DMSO so that the concentration of the MTX solution is 10 mg / mL;

[0074] 240 μL of GN solution and 176 μL of MTX solution were mixed in 384 μL of DMSO to a total volume of 800 μL. The mixture was vortexed to mix well. Due to the weak alkaline conditions, the protonation degree of the bases was lower, and the hydrogen bonds between the bases were easier to form and more stable. Therefore, 25 μL of 4 mg / mL NaOH solution was added to the system. After vortexing for 1 min, ultrasonic treatment was performed for 15 min. The mixed solution was slowly added dropwise to 2 mL of deionized water at 30 ° C and 500 rpm. The mixture was stirred at constant temperature for 1 h. GN and MTX spontaneously formed uniform nanoparticles. After dialyzing (1KD) in deionized water to remove the organic solvent, the base-paired carrier-free nanoparticles formed by self-assembly of the two drugs, namely, the artificial autophagy targeting chimera GM, were obtained.

[0075] The GM obtained above was tested as follows:

[0076] 1. Characterization of particle size, potential and morphology of GM nanoparticles

[0077] The particle size and potential of the GM nanoparticles prepared in Example 3 were measured by dynamic light scattering (DLS), wherein the dispersion medium was water. The morphology of the nanoparticles was observed using a field emission transmission electron microscope (TEM).

[0078] like Figure 5 As shown in Figure 2, the effective particle size of DT nanoparticles is 54.12±4.04nm and the potential is 1.38±0.56. Figure 6 As mentioned above, the TEM results showed that GM nanoparticles had a uniform spherical structure.

[0079] 2. Drug loading and encapsulation efficiency of GM nanoparticles

[0080] The GM nanoparticles prepared in Example 3 were divided into two parts, one part was dialyzed and purified, and the other part was not dialyzed. After freeze-drying using a freeze dryer, they were reconstituted with a small amount of DMSO, and GN and MTX in the HPLC quantitative system were determined. The chromatographic conditions of the HPLC method were: the mobile phase was 0.1% formic acid: acetonitrile = 1:1, the detection wavelength was 254 nm, and the injection volume was 20 μL.

[0081] The encapsulation efficiency and drug loading of the two drugs in GM nanoparticles were calculated according to the formula:

[0082] GN encapsulation efficiency (%) = (GN mass after purification) / (GN mass before purification) × 100%

[0083] MTX encapsulation efficiency (%) = (MTX mass after purification) / (MTX mass before purification) × 100%

[0084] GN drug loading (%) = (GN mass after purification) / (GN mass after purification + MTX mass after purification) × 100%

[0085] MTX drug loading (%) = (MTX mass after purification) / (GN mass after purification + MTX mass after purification) × 100%

[0086] The encapsulation efficiency and drug loading of the two drugs in GM nanoparticles are shown in Table 1:

[0087] Table 1 Encapsulation efficiency and drug loading of two drugs in GM nanoparticles

[0088]

[0089] As shown in Table 1, the encapsulation efficiency of GN was 75.25%, and the encapsulation efficiency of MTX was 80.83%; the drug loading of GN was 35.23%, and the encapsulation efficiency of MTX was 64.77%. The cumulative drug loading of the two drugs reached 100%, indicating that the self-assembled carrier-free nanoparticles have the technical characteristics of high drug loading.

[0090] 3. Stability test of GM nanoparticles

[0091] The GM nanoparticles prepared in Example 3 were added to solvents containing different media (PBS, HEPES), incubated in a shaker at 37°C for 48 h, and the changes in particle size were measured by dynamic light scattering at predetermined time points (0, 0.5, 2, 4, 8, 12, 24, 36, 48 h).

[0092] The results are as follows Figure 7 As shown, the particle size of GM nanoparticles in PBS and HEPES solutions showed almost no significant change in 24 hours, and the PDI showed no obvious fluctuation and was relatively stable, indicating that GM nanoparticles have good stability.

[0093] 4. Self-assembly mechanism test of GM nanoparticles

[0094] In order to explore the self-assembly mechanism of GM nanoparticles, sodium dodecyl sulfate (SDS), urea (Urea) and NaCl were used to destroy the intermolecular forces, and the particle size change was measured by dynamic light scattering. Among them, SDS can destroy the hydrophilic and hydrophobic forces in the molecules, urea can competitively destroy the intermolecular hydrogen bonds, and NaCl can destroy the intermolecular electrostatic effects.

[0095] Equal volumes of SDS, urea and NaCl of corresponding concentrations (0 mM, 20 mM, 40 mM, 60 mM, 80 mM, 100 mM) were added to the GM nanoparticles prepared in Example 3, and the particle size changes were measured after incubation in a shaker at 37°C for 24 h. The results are shown in Table 1. Figure 8As shown in the figure, when NaCl is added, the particle size of the nanoparticles becomes larger, and the particle size increases significantly with the increase of NaCl concentration. Similarly, when Urea is added, the particle size of the nanoparticles also increases with the increase of Urea concentration. However, when SDS is added, there is no obvious change in the particle size of GM nanoparticles. The above results all indicate that electrostatic forces and hydrogen bonding forces drive the self-assembly of GM nanoparticles.

[0096] 5. In vivo targeting evaluation of GM nanoparticles

[0097] Balb / c mice weighing about 20±2g were taken, shaved and injected with 4T1 cells in the third mammary pad to establish a mouse model of breast cancer. 2 After 12 hours, the mice were sacrificed, and the organs and tumor tissues were removed. The fluorescence distribution of the isolated organs was observed by in vivo imaging. Fig. 9 The semi-quantitative results are shown in Fig.10 As shown, the fluorescence intensity of the nanoparticles in the tumor is higher than that of the free fluorescent molecule group. The above results indicate that the nanoparticles have good tumor targeting ability.

[0098] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for preparing an artificial autophagy targeting chimera, characterized in that: The following steps are involved: Guanine derivatives and nucleoside anti-tumor drugs are dissolved in organic solvents respectively, the two solutions are mixed, ultrasonically treated, and then dropped into deionized water for self-assembly to form carrier-free nanoparticles, namely artificial autophagy targeting chimeras; Among them, the structural formula of guanine derivatives is as follows: ; The nucleoside anticancer drug is methotrexate.

2. The method for preparing an artificial autophagy targeting chimera according to claim 1, characterized in that: Guanine derivatives are prepared by the following method: Dissolving compound 1 in a solvent, then adding 4-fluorobenzyl alcohol and a basic catalyst, and reacting at room temperature to obtain compound 2; Compound 2 was used to prepare compound 3 under hydrochloric acid reflux conditions; Compound 3, N-bromosuccinimide and glacial acetic acid react at room temperature to obtain compound 4; Compound 4, N-acetyl-L-cysteine ​​and a base are dissolved in a solvent and reacted at 85-95° C. to obtain compound 5; Compound 5, HATU, DIPEA and NLG8189 were dissolved in a solvent and reacted at room temperature to obtain compound 6; Compound 6 is dissolved in a solvent, and then hydrated lithium hydroxide is added to react at room temperature to obtain a guanine derivative.

3. The method for preparing an artificial autophagy targeting chimera according to any one of claims 1 to 2, characterized in that: Guanine derivative molecules are dissolved in an organic solvent to obtain a guanine derivative solution with a concentration of 8-12 mg / mL; nucleoside anti-tumor drugs are dissolved in an organic solvent to obtain a nucleoside anti-tumor drug solution with a concentration of 8-12 mg / mL.

4. The method for preparing an artificial autophagy targeting chimera according to claim 1, characterized in that: The method also includes adding an alkaline solution into the system, continuing to mix the system, and then ultrasonically treating the system.

5. The method for preparing an artificial autophagy targeting chimera according to claim 4, characterized in that: The alkaline solution is NaOH solution with a concentration of 3-6 mg / mL, and the ultrasonic treatment time is 10-20 min.

6. The method for preparing an artificial autophagy targeting chimera according to claim 1, characterized in that: Also includes: After the self-assembly reaction, dialysis was performed to remove the organic solution.

7. An artificial autophagy targeting chimera prepared by the preparation method according to any one of claims 1 to 6.